Several studies have reported structural brain abnormalities, decreased myelination and oligodendrocyte dysfunction in schizophrenia. In the central nervous system, glia-derived de novo synthesized cholesterol is essential for both myelination and synaptogenesis. Previously, we demonstrated in glial cell lines that antipsychotic drugs induce the expression of genes involved in cholesterol and fatty acids biosynthesis through activation of the sterol regulatory element binding protein (SREBP) transcription factors, encoded by the sterol regulatory element binding transcription factor 1 (SREBF1) and sterol regulatory element binding transcription factor 2 (SREBF2) genes. Considering the importance of these factors in the lipid biosynthesis and their possible involvement in antipsychotic drug effects, we hypothesized that genetic variants of SREBF1 and/or SREBF2 could affect schizophrenia susceptibility. We therefore conducted a HapMap-based association study in a large German sample, and identified association between schizophrenia and five markers in SREBF1 and five markers in SREBF2. Follow-up studies in two independent samples of Danish and Norwegian origin (part of the Scandinavian collaboration of psychiatric etiology study, SCOPE) replicated the association for the five SREBF1 markers and for two markers in SREBF2. A combined analysis of all samples resulted in highly significant genotypic P-values of 9 Â 10 À4 for SREBF1 (rs11868035, odd ration (OR) = 1.26, 95% confidence interval (CI) (1.09-1.45)) and 4 Â 10 À5 for SREBF2 (rs1057217, OR = 1.39, 95% CI (1.19-1.63)). This finding strengthens the hypothesis that SREBP-controlled cholesterol biosynthesis is involved in the etiology of schizophrenia.
Introduction
Despite the estimated high heritability of schizophrenia, the identification of underlying genetic factors has been challenging. So far, more than 130 susceptibility genes have been proposed in schizophrenia by linkage or association studies, most of them awaiting robust replication and identification of functionally relevant genetic variants. 1 Recent reports looking at the overall picture propose that such candidate genes could be grouped in interlinked pathways related to glutamate transmission, synaptic plasticity, oxidative stress, myelination and oligodendrocyte viability. [1] [2] [3] In search of promising candidate genes, studies of gene expression in brain samples from patients with schizophrenia or various cellular and animal models have also been carried out. 4 Using such a functional convergent genomics approach, we investigated transcriptional responses in cultured human glial cells exposed to antipsychotic drugs. We found that some typical and atypical antipsychotics markedly upregulated several genes involved in the biosynthesis of cholesterol and fatty acids. 5, 6 These genes are all controlled by the sterol regulatory element binding protein (SREBP) transcription factors, 7, 8 and we demonstrated that the psychotrophic drugs stimulated cellular lipogenesis through a direct activation of the SREBP proteins. 5, 6 Interestingly, there is now substantial support for abnormalities in lipid biosynthesis and oligodendrocyte function in the brain of patients with schizophrenia, with focus on indicators of disturbed myelination of fiber tracts (for review, Davis et ). Cholesterol is a major component of myelin, and in the brain, cholesterol is synthesized de novo. 10 On this background, in combination with our demonstration of antipsychotic-induced transcriptional activation of the SREBP system, we considered the SREBPs as promising new candidate genes in schizophrenia. There are two different SREBP isoforms, SREBP1 (with two splice variants, SREBP1a and -1c, both encoded by the sterol regulatory element binding transcription factor 1 (SREBF1) gene on chr17p11.2) and sterol regulatory element binding transcription factor 2 (SREBP2) (encoded by the SREBF2 gene on chr22q13.2). Although the different SREBP isoforms overlap in function, SREBP1c controls the expression of fatty acid, phospholipid and triglyceride biosynthetic genes, 11 SREBP2 mainly regulates cholesterol biosynthesis, 8 whereas SREBP1a stimulates the expression of both cholesterol and fatty acid biosynthesis genes, with the later more efficiently activated. 11 The aim of this study was to examine haplotypetagging SNPs (htSNPs) in SREBF1 and SREBF2 for association to schizophrenia in several large case-control samples of German and Scandinavian origin.
Materials and methods
Phase I: Association study of SREBF1 and SREBF2 in a German sample of schizophrenia patients and population-based controls Clinical samples. Psychiatric examinations were approved by the ethics committees of the Faculties of Medicine at the Universities of Bonn, Jena, Heidelberg, and Mannheim. Patients were recruited from consecutive admissions to the inpatient units of the Central Institute of Mental Health in Mannheim, and the Departments of Psychiatry at the Universities of Bonn and Jena. All patient and control subjects gave written informed consent before study participation and are of German descent. A total of 782 patients were interviewed by an experienced psychiatrist or psychologist. Diagnoses were made according to DSM-IV  12 criteria based on an SCID-I   13 interview, medical records and the family history method. We also used the OPCRIT 14 system. Final diagnoses were reached by consensus of at least two investigators using the lifetime best estimate procedure, 15 9.6% of our cases suffered from schizoaffective disorder (n = 77) and were subgrouped according to the criteria used for schizophrenia. The patients' average age was 40.6 ± 13.6 (mean ± s.d.), and their average age-of-onset was 22.9 ± 10.1. The control sample consisted of 839 population-based individuals (481 males, 358 females) with an average age of 44.0 ± 14.02. Genomic DNA was extracted from blood samples using a conventional salting-out protocol. 16 Marker 17 to construct region-specific linkage disequilibrium (LD) and haplotype block maps. Pairwise comparisons of markers > 500 kb apart were ignored, only markers with a minor allele frequency > 0.1%, a Hardy-Weinberg P-value > 0.001, and a marker call rate of > 75% (Haploview defaults) were included in the analysis. Haplotype blocks were defined by the Gabriel et al. 18 algorithm which creates blocks only if 95% of informative comparisons are 'strong LD'. On block analysis, we extended the selection of markers to the complete haplotype blocks they were localized in, that is markers were selected for the whole blocks not just within the candidate gene. Haplotype tagging (ht) SNPs were selected on a block-by-block basis to represent haplotypes of frequencies > 1% in the European population, resulting in 10 markers for SREBF1 and 30 for SREBF2.
Genotyping was performed with the high-throughput BeadArray platform technology from Illumina Inc. (San Diego, CA, USA). Microtitre plates contained mixtures of patients and controls; two individuals were genotyped as technical controls on each plate and genotype replicate consistency was 100%.
Copy number variants in SREBF1 and SREBF2. The Toronto copy number variant (CNV) database (http://projects.tcag.ca/variation/) 19 was searched for putative CNVs localized in SREBF1 or SREBF2. According to this database, there is no CNV spanning the SREBF1 region. Iarfate et al. 20 reported the identification of a deletion on the clone RP5-821D11, which contains the SREBF2 5-UTR, exon 1 and part of intron 1. Since this original report, the Toronto variations located on this clone (12263, 12264 and 27059) have been further defined to an insertion/deletion of 322-327 bp in the MEI1 gene, apparently more centromeric and not overlapping with or affecting the SREBF2 gene. In addition, we screened genome-wide genotype data interrogated by HumanHap550 BeadArrays Illumina, San Diego, USA) available from another study (genome-wide association scan of schizophrenia using about 1400 individuals of German origin, unpublished data) for the existence of putative CNVs using the QuantiSNP program. 21 We did not find any evidence of CNVs in the SREBF1 and SREBF2 genes. 22 The Norwegian Scientific-Ethical Committees, the Norwegian Data Protection Agency, the Danish Scientific Committees, and the Danish Data Protection Agency all approved the study. All patients have given written informed consent before inclusion into the project.
Marker selection and genotyping. The five markers in SREBF1 (rs11654081, rs11868035, rs9907246, rs7503334 and rs7222480) and five markers in SREBF2 (rs1569451, rs133280, rs13055841, rs1052717 and rs2267443) that showed association to schizophrenia (P < 0.05) in the German sample were selected for genotyping in the SCOPE samples. The markers were genotyped using the MassArray system on a Sequenom Compact MALDI-TOF device (Sequenom Inc., San Diego, CA, USA). PCR assay conditions can be obtained from the authors on request. Two percent of individuals were genotyped in duplicate, and there were no replication errors.
Phases 1 and 2: data analysis
Genotypes were quality controlled with the following criteria: individual samples with genotype call rate < 90% and markers with call rate < 96% were excluded from analysis.
Genotyping data were analyzed using the Helix Tree software (HelixTree Genetics Analysis Software, Golden Helix Inc., Bozeman, MT, USA, http://www. goldenhelix.com/SNP_Variation/HelixTree/index.html).
Standard w 2 -test of independence was used to test markers for Hardy-Weinberg equilibrium (HWE); markers with a P-value < 0.001 in controls were excluded. The SNPs were then analyzed as single markers for a logistic regression where the case versus control status was the outcome predicted by the genotypes. The genotypes were also compared with an F-test where bins of one genotype vs the two others were compared with a so-called split analysis (as implemented in Helix Tree, http://www.goldenhelix.com/ SNP_Variation/Manual/split_prediction_methodology. html) to test for dominant, codominant or recessive mode of transmission.
Haplotype trend regression on haplotype block basis and for 2-and 3-markers sliding window were estimated using the expectation-maximization algorithm implemented in Helix Tree (1000 iterations). In order to avoid misleading results caused by multiple rare haplotypes, haplotypes with a frequency less than or equal to 0.05 were clumped together into one group.
A 10 000 shuffles permutation P-value was calculated using the regression module implemented in the Helix Tree software when a P-value < 0.05 was observed.
Combined analysis of the phases 1 and 2 genotypes and samples
To assess the genetic homogeneity of the three populations, the fixation index (F ST ) was calculated by Arlequin 3.1 (cmpg.unibe.ch/software/arlequin3), using the control samples from Norway, Denmark and Germany. The combined analysis was performed with the same allelic and genotypic tests as for phases 1 and 2.
Results
Phase 1: Association analysis in the German case control sample We systematically selected 40 htSNPs from HapMap that entirely cover the SREBF1 (n = 10) and SREBF2 (n = 30) genomic regions, capturing all locus-specific haplotypes at a frequency > 1% in the CEU population (Utah residents with ancestry from northern and western Europe). Both SNP sets were genotyped in a sample of 782 schizophrenia patients and 839 control individuals, all of German origin. For SREBF1 and SREBF2, marker call rates were 99.94 and 99.96%, respectively. Of the SREBF2 SNPs, we excluded rs5758487 because controls were out of HWE (P < 0.005) and rs5758511 because of unreliable genotype clusters.
We analyzed the markers for allelic association by logistic regression and for genotypic association by a split analysis as implemented in Helix Tree (testing for dominant, codominant and recessive models). The results of the single marker analysis in the German sample along with SNP information are displayed in Table 1 . We observed significant association (P-value = 0.046-0.02, allelic test) between schizophrenia and five SREBF1 markers (rs11654081, rs11868035, rs9907246, rs7503334 and rs7222480). The haplotype analysis using two or three markers sliding windows over the 10 SREBF1 markers or over the two HapMap haplotype blocks did not provide additional information (data not shown). The marker rs11654081 had an allelic odd ratio (OR) of 1.18 for T allele (95% confidence interval (CI) (1.03-1.36), data not shown).
We also observed significant association (P = 0.045-0.015, allelic test, see Table 1 ) between schizophrenia and four markers in SREBF2 (rs1569451, rs13055841, rs1052717 and rs2267443) and stronger genotypic association (P = 0.032 to 0.00022, see Table 1 ) with three of these markers (rs13055841, rs1052717 and rs2267443) plus one additional marker (rs133280). These five markers did not show strong pair-wise LD (r 2 < 0.8) except for rs133280-rs1052717 (D 0 = 0.99 and r 2 = 0.96), although these two markers are located in separate blocks (see Supplementary Figure 2_SREBF2 ). For the marker with the strongest allelic association (rs1569451), the allelic OR was 1.20 for the G allele (95% CI (1.03-1.39), data not shown), and for the marker with the strongest genotypic association (rs2267443; A/G), the OR for GG vs AG-AA was 1.41 (95% CI (1.15-1.72), data not shown). Considering the method of selection of the markers (htSNPs), we also performed a haplotype trend regression analysis on a per block basis based on the HapMap version used for the marker selection, with the following blocks: block 1: markers rs7364180-rs1009544, block 2: markers rs133280-rs11702960, block 3: markers rs4822063-rs13055841, block 4: markers rs5751174-rs2267443 Phase 2: Replication in Scandinavian case control samples; and combined analysis On the basis of the association data obtained in the German sample, with a relaxed threshold of uncorrected P-values, all markers that showed significant association (P-value < 0.05) with schizophrenia were selected for replication: rs11654081, rs11868035, rs9907246, rs7503334, rs7222480 for SREBF1; and rs1569451, rs133280, rs13055841, rs1052717, rs2267443 for SREBF2. These ten markers were genotyped in a Danish and in a Norwegian sample (469 and 198 cases, and 874 and 216 controls, respectively, after removing samples that genotyped poorly, i.e. genotype success below 0.9). The rs2267443 marker in SREBF2 had unfortunately a genotyping success rate below 85% and was therefore considered as failed in the replication sample. The other markers were analyzed for allelic and genotypic association as in phase 1.
On the basis of the calculation of a gene-based F ST , we did not find evidence of significant population stratification between the Danish, Norwegian and German control populations (SREBF1 and SREBF2 F ST , P-value = 0.97 and 0.63, respectively). The three study samples were therefore be regarded as genetically homogenous, allowing for analysis of merged samples, and analyzed as: (i) Danish and Norwegian separately, (ii) Danish and Norwegian together and (iii) in total (Danish, Norwegian and German samples merged together).
Association between SREBF1 polymorphisms and schizophrenia in the Scandinavian and merged samples Four of the five SREBF1 markers associated in the German sample were also significantly associated with schizophrenia in the Norwegian sample (P-values = 0.042-0.00084, allelic test) but not in the Danish sample alone, nor in the Danish and Norwegian samples together (see Table 2 ). The diagnostic reliability of the two Scandinavian samples has been ascertained thoroughly and is unlikely to be the cause of this difference. In contrast, the samples are different in other clinical aspects that may confound our findings. Most importantly, the Norwegian patients are generally younger with a shorter duration of illness than the considerably more chronic and poorer outcome of the Danish patients. 22 In the total sample (German, Danish and Norwegian), the association between SREBF1 and schizophrenia was stronger than in the German sample alone (allelic P-value = 0.017-0.0015; Table 2 ). The markers rs11654081 and rs11868035 are in strong LD (D 0 = 1 and r 2 = 0.75, see Supplementary Figure   1_SREBF1 ) and so are the markers rs9907246, rs7503334 and rs7222480 (D 0 = 0.99-1 and r 2 = 0.97-0.99). Actually, the whole SREBF1 gene is located in a region of strong LD, within a Gabriel LD block of 247 kb, 17, 18 which encompasses SREBF1 as well as TOMIL2 (target of myb1 like 2), LRRC48 (leucine rich repeat containing 48), ATPAF2 (ATP synthase mitochondrial F1 complex assembly factor 2) and partially RAI1 (retinoic acid induced 1 gene) and C17orf39 (see Figure 1 ). For further studies we chose to focus on the markers rs11868035 and rs7222480, which had the least LD (D 0 = 0.88 and r 2 = 0.72). The haplotype trend regression for rs11868035-rs7222480 showed a global P-value of 0.012 and a stronger association for the rs11868035_A-rs7222480_T haplotype (P = 0.0032) that remained significant after 10 000 permutations (corrected P-value = 0.034, data not shown).
The odds ratio for rs11868035 and rs7222480 (see Table 3 ), are OR = 1.26 (95% CI (1.09-1.45)) for GG vs AG-AA for the marker and OR = 1.25 (95% CI (1.08-1.44)) for GG vs GT-TT, respectively.
Association between SREBF2 polymorphisms and schizophrenia in the Scandinavian and merged samples Two of the five markers associated with schizophrenia in the German sample were also strongly associated in both the Danish and the Norwegian samples (rs133280 and rs1052717, Table 2 ). However, these two markers are in strong LD (D 0 = 0.98, r 2 = 0.97, see Supplementary Table 2 and Supplementary  Figure 2 ) and are thus likely to pick up the same association signal. For further analysis, we therefore concentrated on the marker rs1052717. The association in the total merged sample (German, Danish and Norwegian) was stronger in the genotypic analysis than the regression analysis (P = 0.000042 vs 0.0090), thus indicating an apparent dominant effect of the rs1052717_A allele rather than a dose-dependent effect (i.e. not linear effect). Interestingly, both the genotypic and allelic associations were stronger with increasing number of samples, that is the association in the total sample was stronger than in any of the national samples on their own, which reflects that the distribution of the associated alleles or genotypes are shifted in the same direction in all populations. On the basis of the genotypic OR for rs1052717 (Table 3) , the risk of having schizophrenia was 1.39 in individuals with genotype AA or AG versus individuals with GG genotype in the total merged sample, with similarly increased ORs (ranging from 1.32 to 1.63) in each of the national samples. Haplotype Trend Regression analysis with sliding windows of two or three markers on the five markers tested in SREBF2 did not provide any additional evidence for a risk haplotype than the data obtained from the association to the single markers (data not shown).
In HapMap on the CEU trios, the associated markers rs133280 and rs1052717 are in LD (D 0 > 0.9 and r 2 > 0.8) with five additional markers (rs7285782, rs9607850, rs2413660, rs714015 and rs133290). Together, these seven markers span most of the gene (from 4.1 kb before exon 1 to intron 11; see Figure 2 ). For the moment, we have not been able to narrow the associated candidate region to a smaller region or a more specific haplotype.
Discussion
We have previously reported that both typical and atypical antipsychotic drugs induce transcriptional upregulation of cholesterol and fatty acid biosynthesis in cultured human glial cells through activation of the sterol regulatory element-binding transcription factors SREBP1 and SREBP2. 5, 6 De novo produced cholesterol is a major component of myelin, 10 and reduced myelination in the brain has consistently been implicated in the pathophysiology of schizophrenia. 2 Against this background, it is interesting that we here report novel association between schizophrenia and several SNPs covering the lipogenesis-controlling SREBF1 and SREBF2 genes. The significant findings were observed in three independent case control samples of German, Norwegian and Danish origin, with several marker allele and genotype distributions for cases versus controls shifted similarly in all samples, thereby giving stronger evidence for association in the merged analysis. a These values remained significant after permutation test with 10 000 shuffles. Figure 1 Sterol regulatory element binding transcription factor 1 (SREBF1) genomic structure and environment with localization of polymorphisms typed. SREBF1 is located on chromosome 17p11.2 in a region of strong linkage disequilibrium (LD). In the present study, haplotype-tagging SNPs (represented by vertical bars) were selected based on the solid spine of LD structure around SREBF1, covering from marker rs3818717 (located in exon 4 of the RAI1 gene) to the marker rs9303144 (5.6 kb from the 3 0 end of C17orf39). The marker G09710 (represented with an arrow) has been associated to schizophrenia and neuroleptic response. 23 The markers associated to schizophrenia in both phases I and II (represented by an *) were mainly located around SREBF1 and in TOM1L2, and are in strong LD with each others. The haplotype-tagging SNPs (htSNPs) (vertical bars) that were screened in the German sample are mapped from the end of CCDC134 (coil-coil domain containing 134), through SREBF2, and TNFRSF13c (Tumor Necrosis Factor Receptor SuperFamily 13C) to CENPM (CENtromer Protein M). All htSNPs significantly associated to schizophrenia in the German population (*) are located in SREBF2. The SNPs rs133280 and rs1052717 (**) were associated to schizophrenia in the three samples and more so in the combined sample. These two markers are in LD with five additional markers (displayed by arrows off rs133280). Those seven markers are located between 4.1 kb 5 0 to the intron 11 of SREBF2.
SREBF1 and SREBF2 as novel loci for schizophrenia susceptibility There is no report of linkage for schizophrenia around the SREBF1 gene per se, but a CAA repeat polymorphism in exon 4 of the neighboring RAI1 gene has been reported as associated with neuroleptic response and schizophrenia. 23 Considering this finding and the strong LD in the region around SREBF1 on 17p11.2, it is possible that the association observed with the RAI1 marker is actually picking up signal from a SREBF1 variant, or vice versa. In dbSNP (http:// www.ncbi.nlm.nih.gov/projects/SNP/) and the scientific literature, several SNPs have been reported to change the amino acid composition of SREBP1 or to influence the level of cholesterol synthesis, [24] [25] [26] but none of these SNPs are deposited in HapMap and we have therefore not been able to conclude on their LD to the associated SNPs of the present study.
The SREBF2 gene is located on chromosome 22q13.2. There have been many reports of linkage between the long arm of chromosome 22 and schizophrenia. Recently, Condra et al. 27 linked the marker D22S270 and markers around SULT4A1, to schizophrenia in a linkage scan of 27 families. These markers are located closed to SREBF2 (0.8 and 1.9 Mb, respectively), and we suggest that SREBF2 could be an interesting and relevant positional candidate for this linkage. There are several known non-synonymous SNPs in SREBF2, but all have frequencies too low to be used for association tests except for rs4822063, which was typed in the phase I on the German population with no significant results.
At the moment, we are not able to explain the functional implication of the association we report, and further replications, higher density genotyping and re-sequencing in both SREBF1 and SREBF2 genes will be necessary to better characterize genetic variants in those genes that could be functionally relevant for susceptibility to schizophrenia.
Abnormalities in myelination and lipid biosynthesis in schizophrenia
There are now several lines of evidence that implicate oligodendrocyte disturbances and myelin defects in schizophrenia (for review, see Davis et al. 2 ). For instance, in an electron microscopy study in 1972, Miyakawa et al. 28 compared a small sample of postmortem biopsies from frontal cortex of patients with schizophrenia and controls. They reported increased amounts of electron dense material in the axon-oligodendrocyte interface and myelin sheats, together with lipofucin-like material in the cytoplasm of oligodendrocytes, whereas astrocytes and microglia were normal. Since this original report, other studies have shown various signs of oligodendrocyte degeneration and myelin sheath abnormalities in prefrontal cortex in brains from patients with schizophrenia. 29, 30 MRI studies using diffusion tensor imaging in vivo have indicated abnormalities in white matter in prefrontal cortex and other brain areas of patients with schizophrenia, indicating the possibility of disturbed maintenance of myelination through oligodendrocytes [31] [32] [33] [34] although not all studies agree. 35, 36 Recently, postmortem gene expression profiling has boosted the field by showing that many myelinrelated genes are downregulated in several brain regions of patients with schizophrenia compared with controls [37] [38] [39] [40] [41] Furthermore, it is interesting to note that while most of the myelination occurs shortly postnatally, 42 the peak of myelination in the cortical areas and especially in the prefrontal cortex occurs during the adolescence and early adulthood, 43, 44 thus coinciding with a critical period for the onset of schizophrenia. 45, 46 Myelin is composed of 70% cholesterol, and impaired cholesterol biosynthesis by disruption of the squalene synthase (an SREBP-controlled gene), has been shown to severely disrupt myelination. 47 The import of cholesterol in the central nervous system is restricted by the blood brain barrier, 10 hence de novo synthesis by glial cells is the major source of cholesterol in the brain. The transcription factors SREBP1 and SREBP2 are key players in the control of genes involved in the synthesis of cholesterol as well as fatty acids, phospholipids and triglycerides. 48 Although SREBP1 and SREBP2 predominantly control the synthesis of fatty acids and cholesterol, respectively, they also overlap in function, especially for the production of cholesterol. 8, 11 When the sterol level becomes low, the SREBP1 and SREBP2 transcription factors are activated in the cell, via activation of a complex formed together with the SREBP cleavage-activating protein (SCAP) and insulininduced gene (INSIG1 and INSIG2) proteins that are essential for sensing and maintaining cholesterol homeostasis. 49 To our knowledge, there is no specific studies so far about the impact of the SREBP pathway in myelination in the central nervous system, but several studies have demonstrated the importance of this pathway in the peripheral myelination of axons. 50, 51 The present implication of SREBF1 and SREBF2 as genetic susceptibility factors in schizophrenia further underscores the importance of lipid biosynthesis and myelination in the pathophysiology of schizophrenia.
As myelin defects have also been observed in affective mood disorders and substance abuse (for review, see refs. 4,52,53), suggesting disturbed myelin as a common, if nonspecific, denominator for a variety of neuropsychiatric disorders, it will be interesting, in future work, to assess the association of SREBF1 and SREBF2 variants in samples of bipolar affective disorder, major depressive disorder or alcohol dependence.
Effects of antipsychotic drugs on myelination
Recent reports have shown that atypical antipsychotic drugs may increase remyelination in a mouse model of demyelination, 54 and also enhance the volume of white matter in patients with schizophrenia. 9, 55 In addition, other reports have shown increased levels of serum lipids in patients treated with
SREBPs genes are associated with Schizophrenia S Le Hellard et al olanzapine or clozapine. 56, 57 Considering these observations together with our previous reports that several antipsychotics (and also some antidepressants) activate the SREBP pathway, 5, 6, 58, 59 and that an upregulation of SREBP-controlled fatty acid biosynthesis-related genes is seen in peripheral blood cells from olanzapine-medicated patients, 60 it raises the hypothesis that some antipsychotic drugs may have a beneficial effect on the negative symptoms and cognitive dysfunctions in schizophrenia through a lipogenic activation and secondary actions on the myelination in the brain. We therefore propose to direct more research toward (i) understanding how some of the existing antipsychotic drugs could act on the myelination level or synaptic function in the brain, (ii) identifying genetic or anatomical (e.g. on MRI scans) markers that may determine subgroups of patients that should benefit the most from these treatment 61 and (iii) establishing genetic tests and clinical interventions to handle patients with higher risks of antipsychotic induced metabolic adverse effect. [61] [62] [63] 
